Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK provides update on belrestotug development programme
GSK with its development partner iTeos Therapeutics, Inc., has confirmed it is ending the development programme for belrestotug.
Download (PDF, 110.2KB) -
GLISTEN phase III trial results show linerixibat significantly improves cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC)
Late-breaking results presented at the European Association for the Study of the Liver (EASL) Congress 2025
Download (PDF, 162.9KB) -
GSK continues to advance the future of respiratory medicine and patient care with new data at ATS
40+ abstracts across GSK’s inhaled and respiratory biologics portfolio
Download (PDF, 189.0KB) -
Nucala (mepolizumab) delivers clinically meaningful and statistically significant reduction in COPD exacerbations, with positive MATINEE trial results published in New England Journal of Medicine
21% reduction in annualised rate of moderate/severe exacerbations in a wide COPD population
Download (PDF, 185.7KB) -
GSK makes strong start to 2025 with growth in sales, profits and earnings
Q1 2025 performance highlights
Download (PDF, 780.9KB) -
Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma
Superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7.
Download (PDF, 245.2KB) -
Arexvy recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices
Over 13 million adults aged 50-59 at increased risk in the US can potentially benefit from RSV immunisation.
Download (PDF, 167.3KB) -
GSK’s 5-in-1 meningococcal vaccine Penmenvy receives positive recommendation from US Advisory Committee on Immunization Practices
Vaccine recommended to help protect persons over 10 years old in the US against disease-causing serogroups of Neisseria meningitidis.
Download (PDF, 182.4KB) -
Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older
Blujepa is the first in a new class of oral antibiotics for uUTIs in nearly 30 years.
Download (PDF, 140.8KB) -
GSK, UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to collaborate on first-of-its-kind dementia research initiative
New collaboration aims to deepen understanding of neurodegeneration using the UK’s unique health data ecosystem.
Download (PDF, 150.0KB) -
GSK’s application to expand use of Nucala (mepolizumab) for the treatment of COPD accepted for review by the European Medicines Agency
Nucala (mepolizumab) could be the first biologic with monthly dosing for patients with COPD, if approved
Download (PDF, 146.5KB) -
ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV
Results from the study demonstrate that N6LS effectively maintained undetectable viral load when combined with long-acting cabotegravir.
Download (PDF, 230.3KB) -
ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP
New data at CROI 2025 show zero cases of HIV acquisition reported with Apretude in varied clinical settings and populations.
Download (PDF, 227.8KB) -
ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor (INSTI) and highly potent capsid inhibitor against HIV-1
Results illustrate ViiV Healthcare’s pipeline is generating multiple options for the development of new ultra long-acting HIV regimens.
Download (PDF, 174.9KB) -
ViiV Healthcare continues to deliver long-acting injectable HIV innovation with late-breaking data and real-world insights across pipeline and portfolio at CROI 2025
Real-world and implementation data highlight effectiveness of Cabenuva and Apretude.
Download (PDF, 205.6KB) -
GSK to showcase latest research at the International RSV Symposium to advance RSV prevention in adults
17 abstracts to evaluate unmet medical need and approaches to RSV prevention in adults.
Download (PDF, 131.7KB) -
Depemokimab applications accepted for review by the US FDA for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps (CRSwNP)
If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing
Download (PDF, 164.3KB) -
Depemokimab delivers clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps (CRSwNP)
ANCHOR-1 and ANCHOR-2 phase III trials show improvements in nasal polyp size and obstruction for depemokimab with twice-yearly dosing.
Download (PDF, 181.4KB) -
GSK plc commences share buyback programme
GSK plc announces the commencement of its share buyback programme, as announced in its 2024 full year results announcement.
Download (PDF, 114.3KB) -
GSK completes acquisition of IDRx, Inc.
GSK plc has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, clinical-stage biopharmaceutical company.
Download (PDF, 143.1KB)
